LXEO250117P7500
- 0.00
- 0.000.00%
Lexeo Therapeutics Newsroom
Express News | Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Press Release: Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Express News | Lexeo Therapeutics Inc Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics
Baird Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $28
Lexeo Therapeutics' Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report
RBC Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $24
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy From RBC Capital
H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Raises Target Price to $23
Promising Developments in Lexeo Therapeutics' LX2006 Program Drive Buy Rating
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Chardan Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Raises Target Price to $25
Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $19
Lexeo Therapeutics GAAP EPS of -$0.89 Misses by $0.24
Express News | Lexeo Therapeutics Inc : Leerink Partners Cuts Target Price to $19 From $20
Lexeo Therapeutics Strengthens Leadership With New Board Appointment
Lexeo Therapeutics | 10-Q: Q3 2024 Earnings Report